A 51-year-old with T2D and BMI 37 kg/m² asks about GLP‑1 RA vs SGLT2 inhibitor for weight loss and CV risk. ASCVD present; eGFR 60. Which is accurate?...

Question

A 51-year-old with T2D and BMI 37 kg/m² asks about GLP‑1 RA vs SGLT2 inhibitor for weight loss and CV risk. ASCVD present; eGFR 60. Which is accurate?

Accepted Answer

GLP‑1 RAs generally produce greater weight loss; both classes offer CV benefit (HF/CKD benefit stronger with SGLT2)

Answer

SGLT2 inhibitors have greater weight loss than GLP‑1 RAs

Answer

Neither class offers CV benefit

Answer

GLP‑1 RAs contraindicated in ASCVD

Answer

SGLT2 inhibitors cannot be used with eGFR 60

us-abim MCQ (SBA): T2D Therapeutics

A 51-year-old with T2D and BMI 37 kg/m² asks about GLP‑1 RA vs SGLT2 inhibitor for weight loss and CV risk. ASCVD present; eGFR 60. Which is accurate?